The estimated Net Worth of Strategic Investments Llcgr... is at least $51.9 Million dollars as of 31 August 2005. Strategic Llcgr owns over 1,770,839 units of Novavax stock worth over $49,178,435 and over the last 19 years Strategic sold NVAX stock worth over $2,691,675.
Strategic has made over 1 trades of the Novavax stock since 2005, according to the Form 4 filled with the SEC. Most recently Strategic sold 1,770,839 units of NVAX stock worth $2,691,675 on 31 August 2005.
The largest trade Strategic's ever made was selling 1,770,839 units of Novavax stock on 31 August 2005 worth over $2,691,675. On average, Strategic trades about 1,770,839 units every 0 days since 2005. As of 31 August 2005 Strategic still owns at least 4,001,500 units of Novavax stock.
You can see the complete history of Strategic Llcgr stock trades at the bottom of the page.
Strategic's mailing address filed with the SEC is 340 EDGEMONT AVE340 EDGEMONT AVE, SUITE 500SUITE 500, BRISTOLBRISTOL, TNTN, 3762037620.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: